secwatch.observer — SEC 8-K summary
======================================

Issuer:     Regen BioPharma Inc (RGBP)
CIK:        0001589150
Form:       8-K
Filed at:   2021-08-31T23:59:59+00:00
Accession:  0001607062-21-000307
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Regen Biopharma files Q2 2021 10-Q, ends reporting delinquency; plans convertible debt settlement to curb dilution
--------------------------------------------------------------------------------

- Filed quarterly report for period ended June 30, 2021; now current on SEC filings.
- No convertible debt issued since July 2020; no plans to issue additional convertible instruments.
- Intends to negotiate settlement of remaining convertible notes to eliminate or limit dilution; no assurances of favorable terms or execution.
- Remaining noteholders may not agree to terms, and any settlement may not be on terms favorable to the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1589150/000160706221000307/0001607062-21-000307-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1589150/000160706221000307/rgbp083121form8k.htm
  HTML page:      https://secwatch.observer/filing/0001607062-21-000307

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer